More MS news articles for June 2004

Biogen Idec, Elan file for European approval of new MS drug

http://triangle.bizjournals.com/triangle/stories/2004/05/31/daily34.html?jst=b_ln_hl

June 4, 2004
Triangle Business Journal

Biogen Idec and Irish partner Elan Corp. have submitted a marketing authorization application to the European Medicines Agency for approval of their multiple sclerosis treatment Antegren.

The drug, which could reach the U.S. market by mid-2005, is being developed as a follow-up to Biogen Idec's top selling drug, Avonex, a multiple sclerosis drug produced at the company's Research Triangle Park facilities.

About 1 million people worldwide suffer from MS, which is a chronic nervous system disease.

Cambridge, Mass.-based Biogen Idec has more than 450 employees at its Research Triangle Park facilities.